Concentric Analgesics has reported positive topline results from its Phase Ib clinical trial of CA-008 for the treatment of post-surgical pain.

The randomised, dose-escalation trial included 40 patients undergoing bunionectomy with standard of care Mayo block, and examined the safety of CA-008 compared to a saline control.

It included five cohorts of eight patients each, with six patients receiving CA-008 at ascending doses and the remaining two receiving control.

Altogether 30 patients received CA-008 at around ten-fold dose range.

The trial’s primary endpoints included the safety and pharmacokinetics of CA-008, while its secondary endpoints were the effect on pain intensity out to two weeks post-surgery and others.

"The long-lasting duration of effect of a single intraoperative injection of CA-008, and the reductions in pain scores compared to control are remarkable."

Results of the trial showed that CA-008 was well tolerated at all dose levels compared to the control group following surgery in bunionectomy patients.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The trial was conducted by Lotus Clinical Research at Huntington Memorial Hospital in Pasadena, California, US.

Lotus Clinical Research chief scientific officer Neil Singla said: “The long-lasting duration of effect of a single intraoperative injection of CA-008, and the reductions in pain scores compared to control are remarkable, particularly as this Phase Ib trial was designed primarily for safety and not powered for efficacy.

“CA-008 showed a better pain response than the control group at nearly every time point in every dose group, a very convincing result.”

Concentric is planning to begin a Phase IIb efficacy study of CA-008 in bunionectomy within this year, with top-line data expected by the end of the year.

CA-008 is a water-soluble pro drug that converts into capsaicin, a naturally occurring molecule that gives chilli peppers their heat.

It can be administered via wide infiltration at the surgical site.